Molplex and AstraZeneca to Collaborate on New Oncology Research Programme
Molplex Pharmaceuticals, a drug discovery company using advanced artificial intelligence systems aimed at reducing the cost and time to develop effective novel treatments, has announced a pioneering new research collaboration agreement with AstraZeneca. The agreement will provide the framework to explore new research approaches to tackle the mechanisms of cancer progression and to translate them into urgently needed effective treatments for cancer patients around the world.
“Despite the progress in cancer research there are still many forms that lack effective treatment,” said Dr David E. Leahy, CEO of Molplex. “This new collaboration - our first with AstraZeneca - will add to our growing portfolio of new potential medicines for controlling and treating multiple forms of cancer, including the more aggressive types. We’re delighted to be embarking on such an important long-term relationship with one of the world’s leading biopharmaceutical companies.”
Bridging the gap between basic research in understanding the causes of cancer and developing new drug-like compounds ready for clinical trials, Molplex will apply its proprietary artificial intelligence systems and advanced laboratory automation to results previously obtained by AstraZeneca's Oncology Innovative Medicines group.
This research aims to accelerate the pace of new drug discovery and increase the number of new oncology drug candidates generated so that more drug candidates can potentially be thoroughly investigated and brought to market.
Scientists from Molplex and AstraZeneca will collaborate on the research project. Molplex will carry out most of the work in R&D phases at its world class facilities at the BioHub, Alderley Park in Cheshire. AstraZeneca will have an option to advance promising lead compounds into preclinical and clinical testing.
Under the terms of the agreement, Molplex will receive payments for any resulting compounds that progress through milestones from discovery to market.
Susan Galbraith, Head of the Oncology Innovative Medicines Unit, AstraZeneca, said “We are pleased to be collaborating with Molplex in the pursuit of new compounds for the treatment of cancer. In particular, we hope that their proprietary ‘Discovery Automation Platform,’ will help to speed discovery of new compounds which we may ultimately be able to develop into treatments for patients with cancer.”
About Molplex Pharmaceuticals
Molplex is a new class of drug discovery company using highly automated decision making systems to identify new treatments and develop portfolios of new medicines for cancer, infection, rare diseases and patients with particular genetic compositions. Bridging the gap between early research and clinic-ready products, Molplex uses proprietary artificial intelligence technology combined with advanced laboratory automation to deliver safer, more effective drugs at a fraction of the traditional cost. The company’s ground-breaking predictive technology and novel therapeutics are expected to improve the lives of over 500 million people worldwide. For more information please visit: www.molplex.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Chief Secretary to the Treasury Danny Alexander visits Molplex
The Chief Secretary to the Treasury of the United Kingdom, the Right Honourable Danny Alexander, visited Molplex on the 16th of October 2014 for a tour of the company's laboratory facilities. Molplex CEO Dr. David Leahy and the rest of the Molplex staff hosted the visit by the minister, which was also used to present a plaque commemorating the opening of the artificial intelligence and robotics laboratories to develop new drugs for cancer, resistant bacteria and personalised medicine.
For more information visit:
Molplex is now hiring at Biohub, Alderley Park.
Molplex is a discovery-driven pharmaceutical business building a commercially attractive pipeline of new drugs in oncology, infection and other therapeutic areas. Founded in 2010 with technology that drives down the rate of failure, we have now won significant new funding to support the expansion of our discovery pipeline. Our ambition for the next 10 years is to create a new major global pharmaceutical business, with growth powered by the invention of high quality pre-clinical candidates for licensing. The new funding will enables us to take a major step towards that ambition and we are looking for equally ambitious people to help us succeed.
We have 17 new positions available at the Biohub facility in Alderley Park, Macclesfield from December 2013. For further information please visit Molplex careers.
Molplex wins UK Government RGF funding to establish an Optiplex laboratory to deliver new drugs for currently untreatable infections
"Department for Business, Innovation and Skills
Selected projects and programmes for the fourth round of the government’s Regional Growth Fund (RGF) will be announced today (Thursday 11 July) by the Deputy Prime Minister, Nick Clegg.
The Deputy Prime Minister announced that 102 companies and projects that applied for funding have been successful, following the most competitive round of the Fund so far.
The companies will take a share of a £506 million pot of funding to attract significant private sector investment and create thousands of jobs across the country."
For more :